Erik Manting
Chief Executive Officer at MENDUS AB
Net worth: 60 707 $ as of 31/03/2024
Profile
Dr. Erik Manting is an Independent Director at TransCode Therapeutics, Inc. and a Chief Executive & Business Officer at Mendus AB.
He is on the Board of Directors at TransCode Therapeutics, Inc. and Synerkine Pharma BV.
Dr. Manting was previously employed as a Founder by Bioentrepreneur BV, a Chief Executive Officer by DCPrime BV, an Executive Director-Life Sciences & Healthcare by Kempen & Co. NV, and an Analyst by Rabo Securities NV.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MENDUS AB
0.21% | 31/12/2022 | 1,442,312 ( 0.21% ) | 60 707 $ | 31/03/2024 |
| 13/12/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Erik Manting active positions
| Companies | Position | Start |
|---|---|---|
| MENDUS AB | Chief Executive Officer | 16/03/2021 |
| TRANSCODE THERAPEUTICS, INC. | Director/Board Member | 20/12/2020 |
Synerkine Pharma BV
 Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Director/Board Member | 01/03/2019 |
Former positions of Erik Manting
| Companies | Position | End |
|---|---|---|
DCPrime BV
 DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Chief Executive Officer | 01/12/2020 |
Kempen & Co. NV
 Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Corporate Officer/Principal | 01/09/2017 |
| Rabo Securities NV | Analyst-Equity | 14/09/2005 |
| Bioentrepreneur BV | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MENDUS AB | Health Technology |
| TRANSCODE THERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Kempen & Co. NV
Kempen & Co. NV Financial ConglomeratesFinance Kempen & Co. NV provides financial services to professional investors. The company's clients include institutional investors, companies, financial institutions, public & semi-public institutions, foundations and high-net-worth private clients. The company was founded in July 1903 by A. J. Kempen and M. D. de Lange and is headquartered in Amsterdam, The Netherlands. | Finance |
| Rabo Securities NV | Finance |
DCPrime BV
DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Health Technology |
Synerkine Pharma BV
Synerkine Pharma BV Miscellaneous Commercial ServicesCommercial Services Synerkine Pharma BV focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company was founded by Hans Preusting in 2018 and is headquartered in Utrecht, Netherlands. | Commercial Services |
| Bioentrepreneur BV |
- Stock Market
- Insiders
- Erik Manting
